Cardiology
Partner With Us
Advertisement
Conexiant chevron_right Cardiology chevron_right From the Journals

From the Journals

thumb description

July 29, 2026

RV Function May Improve Arrhythmic Risk Stratification

A systematic review and meta-analysis linked right ventricular dysfunction to higher odds of sudden cardiac death and severe ventricular arrhythmias, supporting its potential role in complementing conventional risk assessment.

Conexiant

thumb description

July 29, 2026

2025 BP Guideline Could Reduce Mortality

Modeling of nationally representative US data suggested broader implementation of the AHA/ACC 's 2025 recommendations could expand antihypertensive treatment eligibility and reduce long-term mortality among high-risk adults.

Conexiant

thumb description

July 29, 2026

Can Statin Muscle Risk Be Predicted?

Researchers developed and externally validated a prediction model estimating 1-, 5-, and 10-year risks of serious muscle disorders among patients potentially eligible for statin therapy.

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

thumb description

July 22, 2026

Uric Acid May Signal Coronary Calcification

The association with coronary artery calcium persisted following extensive adjustment, whereas carotid plaque findings may be largely explained by cardiometabolic risk factors.

Conexiant

thumb description

July 20, 2026

AHA: Coffee Need Not Be Avoided in AF

Moderate coffee consumption generally appeared safe for most adults, but randomized evidence suggested divergent effects on atrial fibrillation and premature ventricular contractions.

Conexiant

thumb description

July 17, 2026

Can Sugammadex Lower Postsurgical Pulmonary Complications?

A large international randomized trial found fewer postoperative pulmonary complications with sugammadex vs. neostigmine following major abdominal or thoracic surgery, although the difference was driven primarily by reduced atelectasis.

Conexiant

thumb description

July 16, 2026

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

Conexiant